207 related articles for article (PubMed ID: 24703161)
1. MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia.
Ko YC; Fang WH; Lin TC; Hou HA; Chen CY; Tien HF; Lin LI
Leuk Res; 2014 May; 38(5):625-31. PubMed ID: 24703161
[TBL] [Abstract][Full Text] [Related]
2. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
[TBL] [Abstract][Full Text] [Related]
3. Let-7a-3 hypomethylation is associated with favorable/intermediate karyotypes but not with survival in acute myeloid leukemia.
Zhu XW; Yao DM; Wu DH; Wen XM; Yang J; Guo H; Yang L; Deng ZQ; Zhang YY; Qian W; Lin J; Qian J
Tumour Biol; 2016 Jan; 37(1):491-501. PubMed ID: 26227220
[TBL] [Abstract][Full Text] [Related]
4. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia.
Lin TC; Hou HA; Chou WC; Ou DL; Yu SL; Tien HF; Lin LI
Leukemia; 2011 Jan; 25(1):32-40. PubMed ID: 20927134
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
[TBL] [Abstract][Full Text] [Related]
6. Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients.
Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Baranowska A; Siedlecki JA
Leuk Res; 2014 Jul; 38(7):850-6. PubMed ID: 24878001
[TBL] [Abstract][Full Text] [Related]
7. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T
Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation of CCAAT/enhancer binding protein zeta promoter in acute myeloid leukemia.
Yao DM; Qian J; Lin J; Wang YL; Chen Q; Qian Z; Li Y; Wang CZ; Yang J
Leuk Res; 2011 Jul; 35(7):957-60. PubMed ID: 21106240
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.
Lu L; Katsaros D; de la Longrais IA; Sochirca O; Yu H
Cancer Res; 2007 Nov; 67(21):10117-22. PubMed ID: 17974952
[TBL] [Abstract][Full Text] [Related]
10. Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.
Fasan A; Alpermann T; Haferlach C; Grossmann V; Roller A; Kohlmann A; Eder C; Kern W; Haferlach T; Schnittger S
PLoS One; 2013; 8(2):e54365. PubMed ID: 23383300
[TBL] [Abstract][Full Text] [Related]
11. Complexity of miR-223 regulation by CEBPA in human AML.
Eyholzer M; Schmid S; Schardt JA; Haefliger S; Mueller BU; Pabst T
Leuk Res; 2010 May; 34(5):672-6. PubMed ID: 20018373
[TBL] [Abstract][Full Text] [Related]
12. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
13. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
Sarojam S; Raveendran S; Vijay S; Sreedharan J; Narayanan G; Sreedharan H
Asian Pac J Cancer Prev; 2015; 16(9):3785-92. PubMed ID: 25987038
[TBL] [Abstract][Full Text] [Related]
14. Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
Annamaneni S; Kagita S; Gorre M; Digumarti RR; Satti V; Battini MR
Hematology; 2014 Jan; 19(1):42-4. PubMed ID: 23541085
[TBL] [Abstract][Full Text] [Related]
15. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.
Fasan A; Eder C; Haferlach C; Grossmann V; Kohlmann A; Dicker F; Kern W; Haferlach T; Schnittger S
Leukemia; 2013 Feb; 27(2):482-5. PubMed ID: 22814295
[No Abstract] [Full Text] [Related]
16. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
[TBL] [Abstract][Full Text] [Related]
17. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
Fos J; Pabst T; Petkovic V; Ratschiller D; Mueller BU
Blood; 2011 May; 117(18):4881-4. PubMed ID: 21389317
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1.
Peng R; Liu H; Peng H; Zhou J; Zha H; Chen X; Zhang L; Sun Y; Yin P; Wen L; Wu T; Zhang Z
Gene; 2015 Oct; 570(1):57-63. PubMed ID: 26049093
[TBL] [Abstract][Full Text] [Related]
19. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
[TBL] [Abstract][Full Text] [Related]
20. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]